secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2026-05-12T11:35:15+00:00
Accession:  0001193125-26-218194
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Q1 net loss $9.5M; cash $150.3M; XTX501 IND planned mid-2026
------------------------------------------------------------------

- Cash and cash equivalents $150.3M at Mar 31, 2026 (vs $137.5M Dec 31, 2025); runway into early 2028.
- Net loss $9.5M vs $13.3M YoY; collaboration revenue $12.6M (up from $2.9M); R&D $19.8M (up from $8.3M).
- Achieved $6.0M development milestone under AbbVie collaboration (Q2 2026).
- XTX501 IND submission planned mid-2026; Phase 1 start H2 2026; initial data H2 2027.
- Appointed Cheryl R. Blanchard, Ph.D. to board of directors (April 2026).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000119312526218194/0001193125-26-218194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000119312526218194/xlo-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-218194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer